Alot of patients could be treated opening up a huge market for Oncosec and Merck. Orphan drug status comes with price incentives too and market exclusivity for 7 years. Those two factors alone are underestimated also. Sometimes the hare wins the race. Oncosec is about to turn on the jets going into next years data release with PISCES trial.
News 
Market Data 
Discover 
AI
